Potential role for rFVIIa in transfusion medicine.
Hedner
Ulla
U
Novo Nordisk A/S Research and Development, Bagsvaerd, Denmark. uhe@novonordisk.com
Erhardtsen
Elisabeth
E
D000941:Antigens / Q000032:analysis; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D017558:Elective Surgical Procedures; D005167:Factor VII / Q000032:analysis; D005168:Factor VII Deficiency / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D015942:Factor VIIa / Q000235:genetics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000628:therapy; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008107:Liver Diseases / Q000150:complications; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012449:Safety; D013917:Thrombin / Q000096:biosynthesis; D014947:Wounds and Injuries / Q000628:therapy
D000941:Antigens; D011994:Recombinant Proteins; C042580:factor VII clotting antigen; D005167:Factor VII; D015942:Factor VIIa; D013917:Thrombin